Factors affecting efficacy of pegylated interferon alpha-2a in chronic hepatitis C patients with serotype 2

Kanzo/Acta Hepatologica Japonica

Volumn 52, Issue 4, 2011, Pages 236-243

  Irishio, Keiko ^a   Imai, Yasuharu ^a   Mita, Eiji ^b   Toyama, Takashi ^b   Kuzushita, Noriyoshi ^b   Nagase, Toshihiko ^c   Doi, Yoshinori ^d   Yamada, Akira ^e   Michi, Kato ^f   Fukuda, Kazuto ^a   Igura, Takumi ^a   Sawai, Yoshiyuki ^a   Kogita, Sachiyo ^a   Hiramatsu, Naoki ^g   Takehara, Tetsuo ^g   Hayashi, Norio ^h  

^a Ikeda Municipal Hospital   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

^c Suita Municipal Hospital   (Japan)

^d Otemae Hospital   (Japan)

^e SUMITOMO HOSPITAL   (Japan)

^f National Hospital Organizaton Minami Wakayama Medical Center   (Japan)

^g OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h KANSAI ROSAI HOSPITAL   (Japan)

Author keywords

Aged patients; Chronic hepatitis C; Peginterferon alpha 2a; Predictive factors associated with SVR; Serotype 2

Indexed keywords

PEGINTERFERON ALPHA2A; VIRUS RNA;

ARTICLE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTENTION TO TREAT ANALYSIS; SEROTYPE; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE;

EID: 79957598772     PISSN: 04514203     EISSN: 18813593     Source Type: Journal    
DOI: 10.2957/kanzo.52.236     Document Type: Article

References (16)

1. Mann MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965
2. Fried MW, Shiffman ML, Reddy KR et al. Peginter-feron alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
3. Inoue Y, Hiramatsu N, Oze T, et al. Factors affecting efficacy in patients with genotype 2 chronic he-patits C treatment by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses. J Viral Hepat 2010; 17: 336-344
4. Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006; 43: 54-63
5. Imai Y, Tamura S, Tanaka H, et al. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. J Viral Hepat 2010; 17:185-191
6. Zeuzem S, Feinman SV, Rasenack J, et al. Peginter-feron alfa-2a patients with for chronic hepatitis C. N Engl J Med 2000; 343:1666-1672
7. Lee SS, Heathcote EJ, Reddy KR, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepa-tol 2002; 37: 500-506
8. (Japanese Source), 2003; 50:655-672
9. (Japanese Source) 2007; 58:137-149
10. (Japanese Source)
11. Iwasaki Y, Shiratori Y, Hige S, et al. A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a mul-ticenter national study in Japan. Hepatol Int 2009; 3: 468-479
12. (Japanese Source) 2008; 49:417-425
13. Jeong S, Kawakami Y, Kitano M, et al. Prospective study of short-term peginterferon-alpha-2a mono-therapy in patients who had a virological response at 2 weeks after initiation of interferon therapy. J Gastroenterol Hepatol 2008; 23 (4): 541-545
14. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pe-gylated interferon-a and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109
15. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL 28 B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 46: 399-401
16. (Japanese Source) 2006;52: 41-46